InSituPlex
9433 Unraveling the Tumor Microenvironment Using Custom mIF Panels & Spatial Tissue Analysis Copy
poster
webinar

Presented at:

Unraveling the Tumor Microenvironment Using Custom mIF Panels & Spatial Tissue Analysis Copy

shape Monitor
webinar
Angela Vasaturo, PhD

Director of Scientific Affairs, Ultivue

Unraveling the Tumor Microenvironment Using Custom mIF Panels & Spatial Tissue Analysis Copy

1 hour

Relevant for

InSituPlex

Description A persistent challenge in the field of immunotherapy is the fact that only a minority of patients respond to treatment. This is especially true for therapies which rely on immune activation, such as checkpoint inhibitors, due to the complex and heterogeneous immune escape mechanisms which can develop in each patient. Therefore, the development of robust biomarkers, which enable rational patient selection and the design of precise combination therapies, is key for the continued success and improvement of cancer treatments. Multiplex immunofluorescence (mIF) has emerged to complement the conventional IHC by providing highly reproducible, efficient, quantitative, and standardized assays for the analysis of formalin-fixed paraffin-embedded (FFPE) tissue samples. The simultaneous antibody-based detection of multiple markers on a single tissue section can address the low tissue availability from precious and rare donors, establishing mIF as an important assay in the study of the tumor microenvironment and one which can help to maximize the opportunity for patients to benefit from personalized immunotherapies. To enable the transition of mIF assays into clinical applications, a flexible, easy- to- use, and reproducible assay is needed to identify predictive biomarkers. Multiplex immunofluorescence gives researchers the opportunity to study the spatial relationships in the tumor microenvironment, providing access to a wealth of data and information about its immune contexture. The purpose of this presentation is to convey to scientists and pathologists the reasons why reproducible assays are essential for biomarker discovery during clinical trials, how multiplex mIF assays are a great tool for immune profiling the tumor microenvironment, and how spatial tissue analysis can help to make data-driven decisions.

Key Takeaways

Learn why reproducible assays are essential for biomarker discovery

Discover how flexible mIF assays meet the needs for tumor microenvironment research within clinical trials

Gain an understanding of how spatial tissue analysis can help you make data-driven decisions

Meet the presenter

Dr. Angela Vasaturo is Director of Scientific Affairs at Ultivue. Prior to Ultivue, Angela was a Senior Researcher in Dr. Jerome Galon’s Laboratory of Integrative Cancer Immunology at the Cordeliers Research Center. Angela was among the first in Europe to be involved in the development of multiplex IHC and multispectral imaging and analysis of up to six immunofluorescence markers, and today is considered a leading European expert in multiplex IHC techniques, digital pathology, spatial biology, and tissue imaging.

Author
Angela Vasaturo, PhD
Director of Scientific Affairs, Ultivue
Categories: 9248 A novel method to minimize HIER-induced alterations on H&E staining in an integrated mIF-H&E workflow
shape poster
poster

Presented at: AACR 2024

A novel method to minimize HIER-induced alterations on H&E staining in an integrated mIF-H&E workflow

Register here for download

Relevant for

InSituPlex, mIF-H&E fusion

Description Discover a new workflow that enables you to effectively combine H&E staining with mIF InSituPlex® assays and avoid the heat-induced epitope retrieval (HIER) steps that are the root cause of altered H&E staining. We present data showing co-registration of H&E and mIF images with sub-micron accuracy, enabling highly accurate molecular characterization and cellular phenotyping.

Authors

Kevin Hwang, Grace Vezeau, Edyta Olejnik, Douglas Wood, Ruben Cardenes, Lauren Duro, Gourab Chatterjee, Je H. Lee

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 9242 Low-cost, high-sensitivity InSituPlex® mIF assays on the Parhelia Omni-Stainer™
shape poster
poster

Presented at: AACR 2024

Low-cost, high-sensitivity InSituPlex® mIF assays on the Parhelia Omni-Stainer™

Register here for download

Relevant for

InSituPlex, OmniVUE™, U-VUE

Description Our poster presents a simple, rapid, and robust workflow for performing Ultivue InSituPlex® mIF assays with OmniVUE panels on the Parhelia Omni-Stainer. Tight slide temperature control and lower volume reagent used by the Omni-Stainer supports consistent, high performance, high throughput whole slide multiplexed biomarker detection for translational and clinical studies.

Authors

Kevin Hwang, Laura Duro, Alex Veith, Nelson Wedin, Nikolay Samisik, Je H. Lee.

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 8726 Precise and Robust Immune Profiling: Validation of a Flexible Multiplex Immunofluorescence Workflow
shape Monitor
webinar
Yvette Cajigas & Angela Vasaturo, PhD

Director of Product Development at Ultivue, Inc. & Director of Scientific Affairs, Ultivue

Precise and Robust Immune Profiling: Validation of a Flexible Multiplex Immunofluorescence Workflow

1 hour

Relevant for

InSituPlex

Description Though widely recognized that mIF assays have critical implications for clinical translation, validation of mIF staining that allows for flexibility in biomarker selection is a barrier for mIF integration into clinical practice. Join Yvette Cajigas and Angela Vasaturo, experts in assay development and biomarker strategy, and learn about a simple approach to evaluate sensitivity and reproducibility – without sacrificing the flexibility needed to answer biological questions required for evaluating specific treatment options. Take a deep dive into the world of multiplex immunofluorescence and see first-hand how Ultivue’s OmniVUE panels use its patented InSituPlex® technology to advance precision therapies in clinical trials.

Key Takeaways

Understand the challenge of mIF validation and its critical implications for clinical translation

Discover a simple method to assess sensitivity and reproducibility using the InSituPlex® (ISP) staining workflow without sacrificing flexibility

See how single markers in the multiplex ISP assay demonstrate high reproducibility and steric independence, making it a reliable approach.

Meet the presenters

Yvette Cajigas:

Yvette Cajigas is Director of Product Development at Ultivue, and is a board-certified histotechnologist with nearly 2 decades of experience in Anatomic Pathology. She has served as a technical lead at clinical academic and contract research pathology laboratories, and has extensive expertise in histologic technique assay development and multispectral digital pathology.

Angela Vasaturo, PhD

Dr. Angela Vasaturo is Director of Scientific Affairs at Ultivue. Prior to Ultivue, Angela was a Senior Researcher in Dr. Jerome Galon’s Laboratory of Integrative Cancer Immunology at the Cordeliers Research Center. Angela was among the first in Europe to be involved in the development of multiplex IHC and multispectral imaging and analysis of up to six immunofluorescence markers, and today is considered a leading European expert in multiplex IHC techniques, digital pathology, spatial biology, and tissue imaging.

 

Ultivue

Author
Yvette Cajigas

Director of Product Development at Ultivue, Inc.

Author
Angela Vasaturo, PhD

Director of Scientific Affairs at Ultivue, Inc.

Categories: 8019 Unraveling the Tumor Microenvironment Using Custom mIF Panels & Spatial Tissue Analysis
shape Monitor
webinar
Angela Vasaturo, PhD

Director of Scientific Affairs, Ultivue

Unraveling the Tumor Microenvironment Using Custom mIF Panels & Spatial Tissue Analysis

1 hour

Relevant for

InSituPlex

Description A persistent challenge in the field of immunotherapy is the fact that only a minority of patients respond to treatment. This is especially true for therapies which rely on immune activation, such as checkpoint inhibitors, due to the complex and heterogeneous immune escape mechanisms which can develop in each patient. Therefore, the development of robust biomarkers, which enable rational patient selection and the design of precise combination therapies, is key for the continued success and improvement of cancer treatments. Multiplex immunofluorescence (mIF) has emerged to complement the conventional IHC by providing highly reproducible, efficient, quantitative, and standardized assays for the analysis of formalin-fixed paraffin-embedded (FFPE) tissue samples. The simultaneous antibody-based detection of multiple markers on a single tissue section can address the low tissue availability from precious and rare donors, establishing mIF as an important assay in the study of the tumor microenvironment and one which can help to maximize the opportunity for patients to benefit from personalized immunotherapies. To enable the transition of mIF assays into clinical applications, a flexible, easy- to- use, and reproducible assay is needed to identify predictive biomarkers. Multiplex immunofluorescence gives researchers the opportunity to study the spatial relationships in the tumor microenvironment, providing access to a wealth of data and information about its immune contexture. The purpose of this presentation is to convey to scientists and pathologists the reasons why reproducible assays are essential for biomarker discovery during clinical trials, how multiplex mIF assays are a great tool for immune profiling the tumor microenvironment, and how spatial tissue analysis can help to make data-driven decisions.

Key Takeaways

Learn why reproducible assays are essential for biomarker discovery

Discover how flexible mIF assays meet the needs for tumor microenvironment research within clinical trials

Gain an understanding of how spatial tissue analysis can help you make data-driven decisions

Meet the presenter

Dr. Angela Vasaturo is Director of Scientific Affairs at Ultivue. Prior to Ultivue, Angela was a Senior Researcher in Dr. Jerome Galon’s Laboratory of Integrative Cancer Immunology at the Cordeliers Research Center. Angela was among the first in Europe to be involved in the development of multiplex IHC and multispectral imaging and analysis of up to six immunofluorescence markers, and today is considered a leading European expert in multiplex IHC techniques, digital pathology, spatial biology, and tissue imaging.

Author
Angela Vasaturo, PhD
Director of Scientific Affairs, Ultivue
Categories: 6709 Spatially defining the future of cancer biology with advanced multiplexed immunofluorescence
shape Monitor
webinar
Troy Bloom

Senior Field Application Scientist, Ultivue

Spatially defining the future of cancer biology with advanced multiplexed immunofluorescence

30 minutes

Relevant for

InSituPlex

Description Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors. Advances in technology in the past few years have created unprecedented opportunities to identify biomarkers of disease processes, especially by using multi-omics technologies and datasets to derive valid and useful signatures of disease. Despite these advances, today only a minority of patients respond to immunotherapies. Prediction of response to therapies such as checkpoint inhibitors that rely on activation of endogenous immune responses has been shown to be especially difficult due to complex and heterogeneous immune escape mechanisms in each patient. Increasing evidence suggests that measurement of robust biomarkers through spatial analysis of the tissue will be key to enable rational patient selection for an improved clinical trial process and design precise combination therapies. The urgency to discover and implement new biomarkers lays bare the need to integrate a variety of advanced tools to probe the dynamic nature of events happening in the tumor microenvironment (TME). Recently, technology updates integrating the use of multiplex immunohistochemistry/immunofluorescence (mIHC/IF) provides much needed insight into cellular composition, cellular functions, and cell-cell interactions. Importantly, recent studies have used mIHC/IF to explore specific immune cells as part of the tumor immune microenvironment (TME) and found that it is helpful for clinical prognosis and efficacy prediction in patients with cancer. In this presentation we will show a streamlined unique workflow supporting whole slide imaging of an 8-plex mIF and traditional same slide H&E fusion on a single tissue slide for a comprehensive tissue immunophenotyping analysis.

Learning Objectives

The utility of a high throughput, high-plex (Immuno-8) staining and mIF assay development for scientists and clinicians

Demonstrate how advanced AI-driven image analysis can be applied to discover cell types, populations and morphological context

Discuss how whole slide image analysis of the tumor microenvironment can provide insight into specific cancer types

Meet the host

Troy is an experienced analytical histotechnologist with expertise in histology, immunohistochemistry, in situ hybridization, digital slide scanning and image analysis within the GLP/GCP and pre-clinical environments along with a strong multidisciplinary CDx and research experience in models of oncology and autoimmune diseases.

Author
Troy Bloom
Senior Field Application Scientist, Ultivue
Categories: 6163 Co-detection of Protein and RNA biomarkers on FFPE tissue section using InSituPlex® Technology
shape book
ebook

Co-detection of Protein and RNA biomarkers on FFPE tissue section using InSituPlex® Technology

Fill out your details to download

Relevant for

InSituPlex, RNA scope

Description Our eBook outlines the protocol to demonstrate the compatibility of Ultivue InSituPlex® (ISP) assays for protein detection with a commercially available RNAScope® assay (Advanced Cell Diagnostics a bio-techne brand) for RNA detection. This protocol and data shown highlights the value of an integrated ISP-in situ hybridization (ISH) workflow for co-detection of protein and RNA targets on a single FFPE tissue section, showcasing the value of both phenotypic and transcriptomic analyses in the field of spatial biology.

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 6108 Informing Spatial Biology with Multiplexed Immunofluorescence: A Pathologist’s Perspective
shape Monitor
webinar
Sotirios Lakis MD, PhD

Sr. Director Molecular & Computational Pathology, Ultivue

Informing Spatial Biology with Multiplexed Immunofluorescence: A Pathologist’s Perspective

60 minutes

Relevant for

InSituPlex

Description Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors but is challenged in that only a minority of patients respond, especially those therapies that rely on immune activation such as checkpoint inhibitors due to the complex and heterogeneous immune escape mechanisms which can develop in each patient. Therefore, the development of robust biomarkers, enabling rational patient selection and the design of precise combination therapies, is key for the continued success and improvement afforded by this valuable treatment. Overview of what is addressed: Why spatial relationships are important in tumor biology. Examine specific cell clustering, dispersion, and co-localization. To better understand the biology within tissues with a quantitative summary of the regions and phenotypes present.

Webinar Learning Objectives

Enable a better understanding of tumor heterogeneity, its immune environment and contextual relationship using spatial quantification of different immune and tumor cells.

Overview of Spatial Phenomics: Enabling the interrogation of complex cellular phenotypes, functional states, and intercellular relationships with the help of computational biology/pathology methods.

Opportunities and challenges for spatial biology and OMICs applications.

Meet the hosts

As a Senior Director, Molecular and Computational Pathology at UV I am responsible for establishing augmented pathology workflows and for implementing innovative data-driven QC methods. I am a board-certified MD, PhD anatomical pathologist with 10 years of experience in Translational Research, and Cancer Diagnostics.

I am passionate about building cross-disciplinary bridges to deliver innovative services and products while considering the applicable regulatory requirements. I am excited about new ways that molecular and spatial biomarkers can accelerate pharmaceutical research and improve the lives of patients.

Author
Sotirios Lakis MD, PhD

Sr. Director Molecular & Computational Pathology, Ultivue

Categories: 6104 High throughput phenotyping and imaging of the TME using the FlexVUE immunofluorescence assay
shape book
ebook

High throughput phenotyping and imaging of the TME using the FlexVUE immunofluorescence assay

Fill out your details to download

Relevant for

FlexVUE, InSituPlex

Description Our eBook outlines the protocol to demonstrate the compatibility of Ultivue InSituPlex® (ISP) assays for protein detection with a commercially available RNAScope® assay (Advanced Cell Diagnostics a bio-techne brand) for RNA detection. This protocol and data shown highlights the value of an integrated ISP-in situ hybridization (ISH) workflow for co-detection of protein and RNA targets on a single FFPE tissue section, showcasing the value of both phenotypic and transcriptomic analyses in the field of spatial biology.

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 6078 Living in a Spatial World: Characterizing the Immune Environment in Tumors
shape Monitor
webinar
Angela Vasaturo, PhD; Lorcan Sherry, PhD

Associate Director Scientific Affairs, Ultivue; Chief Science Officer, OracleBio

Living in a Spatial World: Characterizing the Immune Environment in Tumors

77 minutes

Relevant for

InSituPlex

Description Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors but is challenged in that only a minority of patients respond, especially those therapies that rely on immune activation such as checkpoint inhibitors due to the complex and heterogeneous immune escape mechanisms which can develop in each patient. Therefore, the development of robust biomarkers, enabling rational patient selection and the design of precise combination therapies, is key for the continued success and improvement afforded by this valuable treatment. Overview of what is addressed: Why spatial relationships are important in tumor biology. Examine specific cell clustering, dispersion, and co-localization. To better understand the biology within tissues with a quantitative summary of the regions and phenotypes present.

Webinar Learning Objectives

Enable a better understanding of tumor heterogeneity, its immune environment and contextual relationship using spatial quantification of different immune and tumor cells.

Overview of Spatial Phenomics: Enabling the interrogation of complex cellular phenotypes, functional states, and intercellular relationships with the help of computational biology/pathology methods.

Opportunities and challenges for spatial biology and OMICs applications.

Meet the hosts

As a Senior Director, Molecular and Computational Pathology at UV I am responsible for establishing augmented pathology workflows and for implementing innovative data-driven QC methods. I am a board-certified MD, PhD anatomical pathologist with 10 years of experience in Translational Research, and Cancer Diagnostics.

I am passionate about building cross-disciplinary bridges to deliver innovative services and products while considering the applicable regulatory requirements. I am excited about new ways that molecular and spatial biomarkers can accelerate pharmaceutical research and improve the lives of patients.

Author
Sotirios Lakis MD, PhD

Sr. Director Molecular & Computational Pathology, Ultivue

Lorcan is an image analysis expert who previously spent 10 years in the pharmaceutical industry as a group leader (Organon, Schering-Plough, Merck & Co.). He led a group responsible for performing histology, immunohistochemistry / image analysis and he has considerable experience in developing translational biomarker strategies for projects across various therapeutic areas. He is a Prince 2® qualified project manager and has extensive experience in study management.

Author
Lorcan Sherry, PhD

Chief Science Officer, OracleBio

Categories: 5903 Development of specific multiplexed immunofluorescence immune assays to study mouse models of tumorigenesis
shape book
ebook

Development of specific multiplexed immunofluorescence immune assays to study mouse models of tumorigenesis

Register here for download

Relevant for

Collaboration, InSituPlex, OmniVUE (formerly FixVUE), OmniVUE (formerly FlexVUE)

Description Developing a multiplex immunofluorescence assay for the in depth characterization of activatedT cells in tumor tissue samples.

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 6083 Importance of Spatial Distribution Insight from Clinical Biopsies
shape Monitor
webinar
Jay Lee, MD, PhD

Director of R&D and Innovation, Ultivue

Importance of Spatial Distribution Insight from Clinical Biopsies

55 minutes

Relevant for

InSituPlex

Description Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors but is challenged in that only a minority of patients respond, especially those therapies that rely on immune activation such as checkpoint inhibitors due to the complex and heterogeneous immune escape mechanisms which can develop in each patient. Therefore, the development of robust biomarkers, enabling rational patient selection and the design of precise combination therapies, is key for the continued success and improvement afforded by this valuable treatment. Overview of what is addressed: Why spatial relationships are important in tumor biology. Examine specific cell clustering, dispersion, and co-localization. To better understand the biology within tissues with a quantitative summary of the regions and phenotypes present.

Webinar Learning Objectives

Enable a better understanding of tumor heterogeneity, its immune environment and contextual relationship using spatial quantification of different immune and tumor cells.

Overview of Spatial Phenomics: Enabling the interrogation of complex cellular phenotypes, functional states, and intercellular relationships with the help of computational biology/pathology methods.

Opportunities and challenges for spatial biology and OMICs applications.

Meet the hosts

As a Senior Director, Molecular and Computational Pathology at UV I am responsible for establishing augmented pathology workflows and for implementing innovative data-driven QC methods. I am a board-certified MD, PhD anatomical pathologist with 10 years of experience in Translational Research, and Cancer Diagnostics.

I am passionate about building cross-disciplinary bridges to deliver innovative services and products while considering the applicable regulatory requirements. I am excited about new ways that molecular and spatial biomarkers can accelerate pharmaceutical research and improve the lives of patients.

Author
Sotirios Lakis MD, PhD

Sr. Director Molecular & Computational Pathology, Ultivue

Categories: 6085 Improving Immuno-Oncology Research Using Spatial Phenomics
shape Monitor
webinar
Keith Wharton, MD, PhD, FCAP

Vice President, Medical Director, Ultivue

Improving Immuno-Oncology Research Using Spatial Phenomics

46 minutes

Relevant for

InSituPlex

Description Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors but is challenged in that only a minority of patients respond, especially those therapies that rely on immune activation such as checkpoint inhibitors due to the complex and heterogeneous immune escape mechanisms which can develop in each patient. Therefore, the development of robust biomarkers, enabling rational patient selection and the design of precise combination therapies, is key for the continued success and improvement afforded by this valuable treatment. Overview of what is addressed: Why spatial relationships are important in tumor biology. Examine specific cell clustering, dispersion, and co-localization. To better understand the biology within tissues with a quantitative summary of the regions and phenotypes present.

Meet the hosts

As a Senior Director, Molecular and Computational Pathology at UV I am responsible for establishing augmented pathology workflows and for implementing innovative data-driven QC methods. I am a board-certified MD, PhD anatomical pathologist with 10 years of experience in Translational Research, and Cancer Diagnostics.

I am passionate about building cross-disciplinary bridges to deliver innovative services and products while considering the applicable regulatory requirements. I am excited about new ways that molecular and spatial biomarkers can accelerate pharmaceutical research and improve the lives of patients.

Author
Sotirios Lakis MD, PhD

Sr. Director Molecular & Computational Pathology, Ultivue

Categories: 5869 Analysis of macrophages to the overall PD-L1 microenvironment using TMAs and InSituPlex
shape poster
poster

Presented at: ASCO 2022

Analysis of macrophages to the overall PD-L1 microenvironment using TMAs and InSituPlex

Register here for download

Relevant for

Collaboration, FixVUE, InSituPlex

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Authors

Marie Cumberbatch, Douglas Wood, Gourab Chatterjee, Christopher Womack, Milan Bhagat, Lorcan Sherry

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5816 Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
shape Monitor
webinar
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer

Length: 46 minutes

Relevant for

FixVUE, InSituPlex

Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.

Webinar Learning Objectives

A better understanding of tumor heterogeneity, its immune environment and contextual relationship requires the spatial quantification of different immune and tumor cells along with the genetic background of the individual cancer.

The utilization of scRNA-seq and multiplexed Immunofluorescence techniques on NSCLC tumors to identify three main populations of intratumoral B and plasma cells.

An overview on the availability of digital tools in histopathology to allow interpreting the high-dimensional complexity of the spatial and immunological heterogeneity in tissue and integrating big (molecular) data to select the best and most effective treatment including combination and advanced therapies.

Meet the host

Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.

Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.

She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.

Author
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: